1.Anesthetic and airway management in a pediatric patient with Morquio Syndrome:A case report
Yves Kristine G. Garcia ; Catherine Renee B. Reyes
Acta Medica Philippina 2024;58(9):35-38
Morquio syndrome is a subtype of mucopolysaccharidoses, wherein the accumulation of glycosaminoglycans (GAGs) in various organ systems lead to alteration of anatomy and physiology. Most prominent features are extensive bony abnormalities, which normally require surgical correction. This paper reports the case of a 7-year-old child with Morquio syndrome who successfully underwent correction of genu valgum under general endotracheal anesthesia via asleep induction and videolaryngoscopy, with supplemental peripheral nerve block. The precautions and anesthetic care done to ensure a safe procedure are discussed, especially with anticipation of a possible difficult airway.
Mucopolysaccharidosis IV
;
Mucopolysaccharidoses
;
Anesthesia
2.Cases of Macular Corneal Dystrophy with a Family History.
Journal of the Korean Ophthalmological Society 1995;36(5):874-878
Macular corneal dystrophy is a heredo-familial disease inherited as an autosomal recessive trait and characterized by corneal opacities due to localized mucopolysaccharidosis. One case of macular corneal dystrophy was reported by Cho et al in Korea in 1976, but it was a case without a family history. We report 3 cases of macular corneal dystrophy with a family history including more specific histopathologic findings and the review of available literatures.
Corneal Opacity
;
Humans
;
Korea
;
Mucopolysaccharidoses
3.Mucopolysaccharidosis and mucolipidosis.
Soo Hee CHANG ; Seng Mi SONG ; Woo Yun SOHN ; Dong Kyu JIN
Hanyang Medical Reviews 2005;25(3):27-36
Mucopolysaccharidosis (MPS) and mucolipidosis(ML) belong to a group of rare genetic disorders of lysosomal enzymes and share some clinical manifestations. MPS is characterized by the accumulation of glycosaminoglycans (GAG) and results from the impaired function of one of 11 enzymes required for normal GAG degradation. ML, which is clinically similar to several forms of MPS, is caused by deficiency of Nacetylglucosamine-1-phosphotransferase activity. Therapeutic strategies for MPS, including enzyme replacement therapy and bone marrow transplantation, have been developed with some success. In this review, we discuss clinical feature, diagnostic methods, management and the present status of research on MPS and ML.
Bone Marrow Transplantation
;
Enzyme Replacement Therapy
;
Glycosaminoglycans
;
Mucolipidoses*
;
Mucopolysaccharidoses*
4.Joys and Sorrows in Mothers of Children with Mucopolysaccharidosis.
Journal of Korean Academy of Child Health Nursing 2011;17(1):58-67
PURPOSE: This study was done to explore the meaning of joys and sorrows in mothers of children with Mucopolysaccharidosis (MPS). METHODS: The participants were 9 mothers who each had a child with MPS. Data were gathered using in-depth interviews. The interviews were recorded and transcribed verbatim. Data were analyzed using Colaizzi method. RESULTS: The significant results from analyzing the interviews can be grouped into 12 concept descriptions, and 5 theme clusters. The essential theme clusters for the experience of the mothers were 'hopelessness about this rare disease', 'guilt because of the disease being hereditary', 'endless courses of treatment', 'wounds in the relationship', and 'relative composure of mind'. CONCLUSION: The finding of this study offer profound information on joys and sorrows experienced by mothers of children with MPS and provide basic data for developing nursing intervention strategies for the mothers of children with rare diseases.
Child
;
Humans
;
Mothers
;
Mucopolysaccharidoses
;
Rare Diseases
;
Child Health
5.A Endotracheal Intubation in a Child with Mocopolysaccharidoses Using the Fiberoptic Laryngoscopy.
Chan Hong PARK ; Sang Hwa LEE ; Sun Kyung CHO ; Bong Il KIM ; Woon Sek RHO ; Byung Ki CHOI
Korean Journal of Anesthesiology 2000;38(6):1089-1091
Mucopolysaccharidoses are a group of inherited disorders of metabolism resulting in the deposition of mucopolysaccharide in various tissues. This leads to organ dysfunction and anatomical abnormalities which can be important to the anesthetist. These abnormalities result in airway difficulty and difficult intubation. We successfully performed endotracheal intubation in a case of mucopolysaccharidoses in a 9-year-old female patient using fiberoptic laryngoscopy.
Child*
;
Female
;
Humans
;
Intubation
;
Intubation, Intratracheal*
;
Laryngoscopy*
;
Metabolism
;
Mucopolysaccharidoses
7.A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients.
Ok Jeong LEE ; Su Jin KIM ; Young Bae SOHN ; Hyung Doo PARK ; Soo Youn LEE ; Chi Hwa KIM ; Ah Ra KO ; Yeon Joo YOOK ; Su Jin LEE ; Sung Won PARK ; Se Hwa KIM ; Sung Yoon CHO ; Eun Kyung KWON ; Sun Ju HAN ; Dong Kyu JIN
Korean Journal of Pediatrics 2012;55(3):88-92
PURPOSE: Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a rare lysosomal storage disorder caused by iduronate-2-sulfatase (IDS) deficiency. MPS II causes a wide phenotypic spectrum of symptoms ranging from mild to severe. IDS activity, which is measured in leukocyte pellets or fibroblasts, was reported to be related to clinical phenotype by Sukegawa-Hayasaka et al. Measurement of residual plasma IDS activity using a fluorometric assay is simpler than conventional measurements using skin fibroblasts or peripheral blood mononuclear cells. This is the first study to describe the relationship between plasma IDS activity and clinical phenotype of MPS II. METHODS: We hypothesized that residual plasma IDS activity is related to clinical phenotype. We classified 43 Hunter syndrome patients as having attenuated or severe disease types based on clinical characteristics, especially intellectual and cognitive status. There were 27 patients with the severe type and 16 with the attenuated type. Plasma IDS activity was measured by a fluorometric enzyme assay using 4-methylumbelliferyl-alpha-iduronate 2-sulphate. RESULTS: Plasma IDS activity in patients with the severe type was significantly lower than that in patients with the attenuated type (P=0.006). The optimal cut-off value of plasma IDS activity for distinguishing the severe type from the attenuated type was 0.63 nmol.4 hr-1.mL-1. This value had 88.2% sensitivity, 65.4% specificity, and an area under receiver-operator characteristics (ROC) curve of 0.768 (ROC curve analysis; P=0.003). CONCLUSION: These results show that the mild phenotype may be related to residual lysosomal enzyme activity.
Enzyme Assays
;
Fibroblasts
;
Humans
;
Iduronate Sulfatase
;
Leukocytes
;
Mucopolysaccharidoses
;
Mucopolysaccharidosis II
;
Phenotype
;
Plasma
;
Sensitivity and Specificity
;
Skin
8.A study of the relationship between clinical phenotypes and plasma iduronate-2-sulfatase enzyme activities in Hunter syndrome patients.
Ok Jeong LEE ; Su Jin KIM ; Young Bae SOHN ; Hyung Doo PARK ; Soo Youn LEE ; Chi Hwa KIM ; Ah Ra KO ; Yeon Joo YOOK ; Su Jin LEE ; Sung Won PARK ; Se Hwa KIM ; Sung Yoon CHO ; Eun Kyung KWON ; Sun Ju HAN ; Dong Kyu JIN
Korean Journal of Pediatrics 2012;55(3):88-92
PURPOSE: Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a rare lysosomal storage disorder caused by iduronate-2-sulfatase (IDS) deficiency. MPS II causes a wide phenotypic spectrum of symptoms ranging from mild to severe. IDS activity, which is measured in leukocyte pellets or fibroblasts, was reported to be related to clinical phenotype by Sukegawa-Hayasaka et al. Measurement of residual plasma IDS activity using a fluorometric assay is simpler than conventional measurements using skin fibroblasts or peripheral blood mononuclear cells. This is the first study to describe the relationship between plasma IDS activity and clinical phenotype of MPS II. METHODS: We hypothesized that residual plasma IDS activity is related to clinical phenotype. We classified 43 Hunter syndrome patients as having attenuated or severe disease types based on clinical characteristics, especially intellectual and cognitive status. There were 27 patients with the severe type and 16 with the attenuated type. Plasma IDS activity was measured by a fluorometric enzyme assay using 4-methylumbelliferyl-alpha-iduronate 2-sulphate. RESULTS: Plasma IDS activity in patients with the severe type was significantly lower than that in patients with the attenuated type (P=0.006). The optimal cut-off value of plasma IDS activity for distinguishing the severe type from the attenuated type was 0.63 nmol.4 hr-1.mL-1. This value had 88.2% sensitivity, 65.4% specificity, and an area under receiver-operator characteristics (ROC) curve of 0.768 (ROC curve analysis; P=0.003). CONCLUSION: These results show that the mild phenotype may be related to residual lysosomal enzyme activity.
Enzyme Assays
;
Fibroblasts
;
Humans
;
Iduronate Sulfatase
;
Leukocytes
;
Mucopolysaccharidoses
;
Mucopolysaccharidosis II
;
Phenotype
;
Plasma
;
Sensitivity and Specificity
;
Skin
10.Carpal Tunnel Syndrome Caused by Persistent Median Artery and Bifid Median Nerve in an Adolescent
Sang Uk LEE ; Hyun Woo LEE ; Sun Young JOO
The Journal of the Korean Orthopaedic Association 2019;54(5):452-456
Carpal tunnel syndrome is rare in children. When it does occur in children, the most common causes reported are mucopolysaccharidosis and mucolipidosis. The median artery is a transitory vessel that develops from the axillary artery in early embryonic life and does not normally survive until postfetal life. In a small percentage of individuals, however, it persists into adulthood and is frequently accompanied by a bifid median nerve. A persistent median artery can be a cause of carpal tunnel syndrome in adults, but it is extremely rare in children and adolescents. This paper reports a case of a carpal tunnel syndrome caused by a persistent median artery and bifid median nerve in a 13-year-old girl.
Adolescent
;
Adult
;
Arteries
;
Axillary Artery
;
Carpal Tunnel Syndrome
;
Child
;
Female
;
Humans
;
Median Nerve
;
Mucolipidoses
;
Mucopolysaccharidoses